Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sbpgroup.com
(Stock code: 1177)

ENTER INTO PARTNERSHIP WITH BOEHRINGER INGELHEIM WITH POTENTIAL TOTAL DEAL VALUE OF US$7 BILLION

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Group has entered into a strategic option and license agreement (the "**Agreement**") with Boehringer Ingelheim This marks the second agreement between the parties in the oncology field, reflecting shared commitment to establishing a long-term strategic partnership.

The Agreement covers a total of six preclinical asset programs (the "**Programs**") spanning antibody-drug conjugates (ADCs) and T-cell engagers (TcEs), five of which center on LaNova Medicines (Shanghai) Co., Ltd. ("**LaNova Medicines**"), a wholly-owned subsidiary of the Group. The remaining program comes from Beijing Tide Pharmaceutical Co., Ltd. ("**Beijing Tide**"), another subsidiary of the Group.

Pursuant to the Agreement, the Group will lead the early development of the Programs through the completion of global Phase I clinical trials. Upon achievement of the agreed clinical milestones, Boehringer Ingelheim is entitled to exercise its option to acquire exclusive rights to develop, manufacture and commercialize (i) four of the Programs worldwide excluding Mainland China, Hong Kong and Macau, and (ii) the remaining two worldwide.

The Group will receive US$358 million in upfront and near-term payments and is eligible for potential option-exercise, development, regulatory and commercial milestone payments of US$7 billion, plus up to double-digit royalties on future product sales.

The partnership with Boehringer Ingelheim marks an important milestone in the Group's international innovation strategy and further validates the strength of its scientific capabilities in next-generation oncology. By combining the Group's innovative platforms and early-development capabilities with Boehringer Ingelheim's global oncology expertise, both parties aim to maximize the potential of these programs and bring innovative treatment options to patients worldwide.

About Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at http://www.boehringer-ingelheim.com/

About LaNova Medicines and Beijing Tide

LaNova Medicines serves as the Group's differentiated oncology and immunology innovation engine, with over 20 innovative R&D programs and four core technology platforms, and its R&D capabilities have been validated through collaborations with multiple multinational pharmaceutical companies. Beijing Tide focuses on therapeutic areas including pain management and respiratory diseases, with over 20 innovative R&D programs. Centered on its advanced drug delivery platform, Beijing Tide has leveraged AI technologies to achieve major breakthroughs across multiple drug modalities.

The Board considers that the entering into of the Agreement is in the best interests of the Company and its shareholders as a whole, and will enable the Group to fully realize the scientific and commercial value of its technology platforms.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 4 November 2026

As at the date of this announcement, the Board of the Company comprises five executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y and Mr. Tse Hsin and six independent non-executive Directors, namely Mr. Lu Zhengfei, Ms. Lu Hong, Mr. Zhang Lu Fu, Dr. Li Kwok Tung Donald, Dr. Chen Lieping and Dr. Lu Bai.